P2RY12 and myocardial infarction: In a meta-analysis and modelling study using data from 100 000 participants randomised to P2Y12 inhibitors and over 45 000 patients from the Scottish population hospitalised with myocardial infarction, we examined relative and absolute treatment effects for newer P2Y12 inhibitors.